Arcturus Therapeutics (ARCT) Competitors $12.50 -0.31 (-2.39%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. CALT, AMPH, ARDX, DYN, AUPH, SNDX, BGM, ADPT, IOVA, and WVEShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Ardelyx Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Adaptive Biotechnologies Iovance Biotherapeutics Wave Life Sciences Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community favor CALT or ARCT? Arcturus Therapeutics received 420 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 66.32% of users gave Arcturus Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Arcturus TherapeuticsOutperform Votes44766.32% Underperform Votes22733.68% Does the media favor CALT or ARCT? In the previous week, Arcturus Therapeutics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Arcturus Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Arcturus Therapeutics' average media sentiment score of 1.55 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Arcturus Therapeutics Very Positive Which has higher earnings and valuation, CALT or ARCT? Arcturus Therapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Arcturus Therapeutics$138.39M2.43-$29.73M-$3.01-4.12 Do analysts recommend CALT or ARCT? Calliditas Therapeutics AB (publ) currently has a consensus target price of $39.25, indicating a potential downside of 1.88%. Arcturus Therapeutics has a consensus target price of $59.20, indicating a potential upside of 377.15%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do insiders & institutionals have more ownership in CALT or ARCT? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CALT or ARCT? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.41, suggesting that its stock price is 241% more volatile than the S&P 500. Is CALT or ARCT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Arcturus Therapeutics -36.39%-22.39%-14.81% SummaryArcturus Therapeutics beats Calliditas Therapeutics AB (publ) on 16 of the 19 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$338.13M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-5.627.3722.5818.55Price / Sales2.43242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book1.196.486.704.26Net Income-$29.73M$143.68M$3.23B$248.39M7 Day Performance-3.75%1.79%1.26%1.27%1 Month Performance31.57%6.68%3.75%3.85%1 Year Performance-55.55%-2.73%15.78%5.23% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.9865 of 5 stars$12.55-2.0%$59.20+371.7%-49.9%$341.14M$138.39M-5.67180News CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.505 of 5 stars$23.50+0.6%$43.50+85.1%-40.8%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5698 of 5 stars$4.56-5.4%$10.61+132.7%-13.9%$1.09B$333.62M-28.5090Positive NewsDYNDyne Therapeutics3.3279 of 5 stars$9.33+14.2%$47.46+408.7%-53.4%$1.06BN/A-2.62100Short Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.6538 of 5 stars$7.66-1.2%$11.50+50.1%+61.9%$1.05B$235.13M-51.06300SNDXSyndax Pharmaceuticals3.6563 of 5 stars$11.93+3.4%$36.20+203.4%-33.0%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298ADPTAdaptive Biotechnologies4.1439 of 5 stars$6.83-6.8%$9.40+37.6%+180.9%$1.01B$178.96M-6.27790News CoveragePositive NewsGap DownIOVAIovance Biotherapeutics4.5731 of 5 stars$3.08+0.7%$18.22+491.6%-69.5%$1.01B$164.07M-2.07500Upcoming EarningsWVEWave Life Sciences4.3154 of 5 stars$6.12+3.4%$22.18+262.4%+56.6%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Amphastar Pharmaceuticals Alternatives Ardelyx Alternatives Dyne Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Qilian International Holding Group Alternatives Adaptive Biotechnologies Alternatives Iovance Biotherapeutics Alternatives Wave Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARCT Stock Free ARCT Stock Alerts